OP0034 Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the detect cohort
C Mihai(Carol Davila University of Medicine and Pharmacy), O Distler(University Hospital Zurich), Janet Pope(St Joseph's Health Care), D. M. Rosenberg(Actelion (Switzerland)), JR Seibold(Scleroderma Foundation), D Bondermann(Medical University of Vienna), E Grünig(Heidelberg University), D Khanna(Center for Rheumatology), U Müller-Ladner(Justus-Liebig-Universität Gießen), M Antic(University Hospital Zurich), G Coghlan(Institute of Cardiology), H Chadha-Boreham(Actelion (Switzerland)), R Dobrota(Carol Davila University of Medicine and Pharmacy), CP Denton(The Royal Free Hospital), VV McLaughlin(University of Michigan), M.C. Vonk(Radboud University Nijmegen), M Doelberg(Actelion (Switzerland))
Cited by 1
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
|New England Journal of Medicine|1997|694
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503